ALGS
Aligos Therapeutics, Inc.
+0.16 (+3.17%)5.21USD8.7K成交股數222M市值–本益比(近四季)59.4股價營收比-100.0%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 0.00-100% | 2.8M+367% | 741K-41% | 965K-9% | 311K-55% | 606K-44% | 1.3M-71% | 1.1M+658% | 694K | 1.1M | 4.3M | 140K |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 24.1M | 23.4M | 23.9M | 14.0M | 14.5M | 16.0M | 16.8M | 21.1M | 16.4M | 15.9M | 16.8M | 18.1M |
| 銷售管理費用 | 5.6M | 6.4M | 5.2M | 5.6M | 5.1M | 5.2M | 4.6M | 6.4M | 6.7M | 6.4M | 9.2M | 8.5M |
| 營業利益 | −1.9M-90% | −26.9M+31% | −28.4M+41% | −18.6M-30% | −19.2M-13% | −20.6M+8% | −20.1M+5% | −26.4M+10% | −22.0M | −19.1M | −19.1M | −23.9M |
| 營業利益率 | – | -951.6% | -3,827.4% | -1,924.0% | -6,187.5% | -3,393.2% | -1,610.5% | -2,489.5% | -3,176.7% | -1,757.7% | -445.8% | -17,084.3% |
| 稅後淨利 | −1.5M-103% | −23.0M-72% | −31.5M+64% | −15.9M-413% | 43.1M-224% | −82.2M+355% | −19.3M+2% | 5.1M-122% | −34.9M | −18.0M | −18.8M | −23.0M |
| 淨利率 | – | -814.1% | -4,256.0% | -1,643.8% | 13,854.7% | -13,556.1% | -1,540.7% | 477.0% | -5,023.5% | -1,662.8% | -437.6% | -16,396.4% |
| 稀釋 EPS | -0.14-93% | -2.21-83% | -3.04-1% | -1.53-289% | -2.11-62% | -13.10+26% | -3.07+614% | 0.81-253% | -5.58 | -10.37 | -0.43 | -0.53 |
| 稀釋股數 | 10.4M | 10.4M | 10.4M | 10.4M | 8.7M | 6.3M | 6.3M | 6.3M | 6.2M | 1.7M | 43.2M | 42.9M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 30.4M | 30.0M | 41.9M | 18.7M | 73.8M | 37.0M | 35.3M | 45.1M | 24.2M | 70.4M | 90.8M | 78.7M |
| 應收帳款 | 27.8M | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 66.3M | 64.6M | 110M | 135M | 151M | 70.1M | 88.4M | 109M | 128M | 85.9M | 106M | 122M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 34.4M | 32.8M | 37.9M | 32.8M | 34.3M | 99.1M | 38.3M | 41.6M | 68.1M | 31.0M | 36.5M | 37.0M |
| 股東權益 | 31.9M | 31.8M | 71.8M | 102M | 116M | −29.0M | 50.1M | 67.2M | 59.8M | 54.8M | 69.6M | 84.8M |
| 負債比 | 51.9% | 50.8% | 34.6% | 24.4% | 22.7% | 141.3% | 43.3% | 38.2% | 53.2% | 36.1% | 34.4% | 30.4% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −23.1M | – | – | −20.9M-8% | – | – | – | −22.7M | – | – | −22.4M |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | 7K |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | −22.4M |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | -15,995.7% |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 2.2M | -39.5% | −24.2M | -1,106.7% | -2.45 | – |
| FY2024 | 3.6M | -41.7% | −131M | -3,633.6% | -20.94 | −80.9M |
| FY2023 | 6.2M | – | −87.7M | -1,416.2% | -34.20 | −79.0M |
| FY2022 | 0.00 | – | −96.0M | –% | -2.25 | −80.3M |
| FY2021 | 0.00 | – | −128M | –% | -3.22 | −117M |
| FY2020 | 0.00 | – | −109M | –% | -10.87 | −76.3M |
| FY2019 | – | – | −52.3M | –% | -26.04 | −49.6M |